Bisphenol A epoxy resin diacrylate ester is a synthetic polymer commonly used in various applications due to its excellent adhesion, mechanical strength, and optical clarity. It is synthesized through a multi-step process that involves reacting bisphenol A with epichlorohydrin to form an epoxy resin, followed by a reaction with acrylic acid to introduce acrylate groups. The presence of acrylate groups allows for cross-linking and polymerization, leading to the formation of a rigid and durable material. This compound is often used in dental composites, adhesives, coatings, and sealants. Its wide range of applications has led to extensive research focusing on its properties, potential health effects, and environmental impact. Studies have indicated that bisphenol A epoxy resin diacrylate ester may exhibit cytotoxic and genotoxic effects in certain cell types. Researchers are investigating its biocompatibility, potential for leaching into the environment, and the development of safer alternatives. The compound's importance stems from its versatility and affordability, but ongoing research aims to address potential concerns and ensure its safe and responsible use.'
bisphenol A epoxy resin diacrylate ester: prepolymer in ultraviolet curing inks; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 92212 |
| SCHEMBL ID | 195095 |
| MeSH ID | M0093826 |
| Synonym |
|---|
| 4687-94-9 |
| bisphenol a glycerolate (1 glycerol/phenol) diacrylate, contains mehq as inhibitor |
| einecs 260-731-8 |
| diacrylic acid, diester with 3,3'-(isopropylidene)bis(p-phenyleneoxy)di(propane-1,2-diol) |
| [2-hydroxy-3-[4-[2-[4-(2-hydroxy-3-prop-2-enoyloxypropoxy)phenyl]propan-2-yl]phenoxy]propyl] prop-2-enoate |
| A-3002 , |
| sp 1509 |
| photomer 3015 |
| ripoxy sp 1509 |
| unii-615t9xd11q |
| actocryl 400 |
| epoxy ester 3000a |
| kayarad r 115 |
| diclite ue 8200t |
| vr 77 |
| bisphenol a epoxy resin diacrylate ester |
| epotuf 91-275 |
| ebecryl 3700 |
| bisphenol a glycerolate diacrylate |
| novacure 3700 |
| 57417-94-4 |
| ebecryl 3704 |
| pn 1570 |
| ebecryl 600 |
| bisphenol a diether with glycidyl acrylate |
| ripoxy vr 77 |
| bisphenol a bis(3-acrylato-2-hydroxypropyl) ether |
| agisyn 1010 |
| epa 37 |
| ebecryl 3720tp40 |
| bisphenol a diglycidyl ether acrylate |
| einecs 225-144-3 |
| a 3002 |
| celrad 3600 |
| eb 3700 |
| morcure 2000 |
| eb 600 |
| bisphenol a diglycidyl ether diacrylate |
| 615t9xd11q , |
| 2-propenoic acid, (1-methylethylidene)bis(4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)) ester |
| celrad 3700 |
| (1-methylethylidene)bis(4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl)) diacrylate |
| bisphenol a glycerolate (1 glycerol/phenol) diacrylate |
| AKOS015894400 |
| 2-propenoic acid, (1-methylethylidene)bis(4,1- phenyleneoxy(2-hydroxy-3,1-propanediyl)) ester |
| (1-methylethylidene)bis(4,1-phenyleneoxy(2-hydroxy-3,1- propanediyl)) diacrylate |
| acrylic acid, 1,1'-diester with 3,3'-(isopropylidenebis(p-phenyleneoxy))di-1,2-propanediol |
| 2-propenoic acid, 1,1'-((1-methylethylidene)bis(4,1-phenyleneoxy(2-hydroxy-3,1-propanediyl))) ester |
| SCHEMBL195095 |
| mfcd01317012 |
| bisphenol a-bis(2-hydroxypropyl)acrylate |
| 2,2-bis[4-(2-hydroxy-3-acryloxypropoxy)phenyl]-propane |
| 3,3'-(4,4'-(propane-2,2-diyl)bis(4,1-phenylene))bis(oxy)bis(2-hydroxypropane-3,1-diyl) diacrylate |
| bisphenol a glycerolate(1 glycerol/ |
| VZTQQYMRXDUHDO-UHFFFAOYSA-N |
| Q27263300 |
| bisphenol a glycerolate (1 glycerol/ |
| 2,2-bis[4-(3-acryloyloxy-2-hydroxypropoxy)phenyl]propane |
| DTXSID40863439 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 4 (30.77) | 18.7374 |
| 1990's | 4 (30.77) | 18.2507 |
| 2000's | 3 (23.08) | 29.6817 |
| 2010's | 2 (15.38) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.52) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 6 (40.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 9 (60.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||